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Abstract:
“Young-onset dementia” (YOD) includes clinical presentations of dementia with the onset before age 
of 65. There are several important clinical differences between much more frequent late onset dementia 
(LOD) and YOD syndromes. First, YOD has much wider range of different aetiologies comparing to 
LOD. Among all possible aetiologies, treatable/potentially reversible causes are much more common 
in YOD then in LOD. There is also significantly higher prevalence of inherited dementias in younger 
age-groups. Furthermore, atypical cognitive (non-amnestic) presentations of common degenerative de-
mentias (e. g. Alzheimer’s disease) are more frequent in YOD. Therefore, routine cognitive evaluation 
using standard screening tests (e.g. MMSE) may be insufficient. YOD is more often accompanied by 
neurological and systemic features (dementia plus syndromes) and the identification of these features 
can aid the diagnosis. 
Based on these specificities of YOD, diagnostic approach is always challenging. Therefore, a thorough 
neurocognitive assessment and a structured and rational diagnostic approach is mandatory to ensure 
early diagnosis and treatment.
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Sažetak:
Demencije s počekom u ranoj životnoj dobi-praktični pristup oboljelom 
Demencije s počekom u ranoj životnoj dobi (engl. Young-onset dementia, YOD) označavaju pojavu 
demencije prije 65. godine života. Postoji nekoliko važnih kliničkih razlika između mnogo učestalijih 
demencija koje počinju iza 65. godine života (engl. Late-onset dementia, LOD) i YOD. Prvo, YOD 
ima mnogo širi raspon različitih uzroka u usporedbi s LOD-a. Među svim mogućim etiologijama, kod 
demencija ranog početka mnogo su češći izlječivi/potencijalno reverzibilni uzroci demencije. Također 
je znatno češća nasljedna komponenta u demencijama s početkom u mlađim dobnim skupinama. Na-
dalje, atipične kognitivne (ne-amnestičke) prezentacije uobičajenih degenerativnih demencija (npr. Al-
zheimerove bolesti) češće su u YOD. Stoga kognitivna procjena pomoću standardnih screening testova 
(npr. MMSE testa) može biti neadekvatna. YOD je češće popraćen neurološkim i sistemskim simpto-
mima i znakovima (demencija plus sindromi), a prepoznavanje tih značajki može pomoći u dijagnozi. 
Na temelju tih specifičnosti YOD-a, dijagnostički pristup uvijek predstavlja veliki izazov. Stoga 
je u pristupu oboljelom potrebna detaljna neurokognitivna procjena te strukturiran i racionalan 
dijagnostički pristup kako bi se osigurala rana dijagnoza i liječenje.
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Introduction
Decades ago, the term “presenile dementia“ has been replaced 
with terms “young(er)/early-onset dementia” (YOD) that include 
patients with early onset of dementia (before age of 65). The 
diagnosis of YOD presents a particular challenge for cognitive 
neurologist and, although not so common among all dementia 
cases (approximately 8% of all dementia cases)1,2, it is recognised as 
a growing socioeconomic problem, since it affects working popula-
tion. While the main and predominant cause of dementia in older 
age is sporadic Alzheimer’s disease (AD), YODs have much wider 
range of different aetiologies with higher percentage of potentially 
curable causes and a higher prevalence of inheritance1,2. Due to 
younger age, broad differential diagnosis, common non-amnestic 
cognitive presentations that can be missed by standard screening 
tests and frequent presence of other neurological and systemic 
symptoms, diagnostic approach is always challenging. Therefore, a 
structured and rational diagnostic approach is necessary to ensure 
early treatment and prevent progression of the disease if possible1-4. 
The intent of this short review is to emphasize specific clinical fea-
tures of YOD group and to provide current evidence for complex 
diagnostic approach to patient with YOD. 
Aetiology of YOD
The aetiology of YODs is broad (Table 1.) (adapted from 5). 
AD, vascular cognitive impairment (VCI), frontotemporal lobar 
degeneration (FTLD) and diffuse Lewy body dementia (DLBD) 
are the most common causes of dementia both in elderly and 
in younger patients (Figure 1.)6. If the presentation of dementia 
is before age of 45, neurodegenerative dementia accounts for 
30% of cases (with a rare presentation of AD), autoimmune and 
inflammatory causes account for 20%, and nearly in 20% of 
dementia cases the cause remains unknown7.
Table 1. Etiology of young-onset dementia (according to Sampson et al.)5 
 
 
*potentially treatable cause 
Primary neurodegenerations 
Alzheimer's disease 
Frontotemporal lobar degeneration 
Dementia with Lewy bodies 
Multiple system atrophy 
Corticobasal degeneration 
Parkinson's disease 
Progressive supranuclear palsy 
 






Vasculitis associated with systemic disorders* 



















Subacute sclerosing panencephalitis 
Progressive multifocal leukoencephalopathy 
 

















Chronic subdural haematoma* 
 
Obstructive sleep apnea* 
 
Table 1. Etiology of young-onset dementia (according to Sampson et al.)5
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A practical approach
The clinical assessment of a patient with dementia should be the 
same regardless of age. However, having a wide range of poten-
tially curable causes, a structured and more detailed approach is 
essential. The first step is to obtain a detailed history (the onset 
and course of the disease, initial symptoms, personality and 
mood changes, changes in everyday activities and lifestyle, for-
mer and present psychiatric diseases). That information should 
best be gathered from an informant who knows the patient well, 
because the information given by the patient is often not reliable. 
The following steps include a thorough general and neurological 
examination and neurocognitive assessment that may nar-
row the differential diagnosis1-5. Red flag clinical presentations 
that should alert neurologist to perform cognitive screening 
in middle-aged people are: treatment-resistant depression or 
anxiety, especially if there are subjective cognitive complaints; 
patients presenting with memory or other cognitive problems, 
especially with positive family history of young onset dementia; 
concern about the patient’s cognition from close family member; 
behaviour changes inconsistent with the premorbid personality; 
5 or more years of heavy alcohol or substance abuse; HIV-posi-
tive status; progression of neurological problems; family history 
of YOD and chronic systemic disease known to cause dementia1.
Pattern of the cognitive deficit
YOD may often initially be presented with non-amnestic defi-
cits, which can be missed with routine screening tests (e.g. Mini 
Mental State Examination (MMSE)8, already validated for Croa-
tian population9); therefore, a thorough cognitive assessment 
with evaluation of each cognitive domain (i.e. memory, speech, 
executive and perceptual functions, praxia and other) is essential 
for detecting cognitive deficits and determining the exact pattern 
of cognitive dysfunction. Moreover, it is important to recognise 
different types of cognitive impairment within cognitive domain, 
e.g. in the memory domain, impairment of episodic memory, 
distinctive for AD, should be distinguished from semantic mem-
ory impairment, characteristic for semantic dementia (SD)10. 
The patient’s history (both acquired from the patient himself and 
people close to him) about everyday activities, changes in lifestyle 
and personality can direct to the pattern of cognitive deficit1-5.
A useful distinction between cortical and subcortical dementias 
can be made at the beginning of the evaluation. Patients with 
cortical dementias can differ in the pattern of cognitive impair-
ment early at the onset of symptoms (e.g. effortful, non-fluent 
speech in progressive non-fluent aphasia (PNFA), visuopercep-
tual and visuospatial deficits in posterior cortical atrophy (PCA) 
or loss of semantic knowledge in SD) with relative preservation 
Figure 1. Epidemiology of young-onset dementia (according to Harvey et al.)6
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of psychomotor speed. By contrast, subcortical dementias (e.g. 
brain small vessel disease, dementia involving basal ganglia) 
is characterised by profound slowing of psychomotor speed11, 
executive dysfunction, and impairment of memory retrieval (free 
recall) with preservation of guided memory retrieval (cued recall) 
and is commonly accompanied by additional neurological and/
or systematic features (motor weakness, sensory loss, changes in 
myotatic reflexes etc.).
Low score on verbal fluency test (the patient is asked to name as 
many words starting with an assigned letter in given time) might 
be a useful non-specific indicator of cognitive dysfunction12 and 
can additionally narrow the differential diagnosis13.
Episodic memory impairment, besides in AD, can be a dominant 
feature of temporal lobe epilepsy, limbic encephalitis, paraneo-
plastic syndrome, autoimmune connective tissue diseases etc. Pa-
rietal (visuospatial or visuoperceptual deficits, dyslexia, dysgraph-
ia, dyscalculia, or apraxia) or occipital (visual disorientation and 
impaired early visual processing) dysfunction is typical of PCA, 
but can also occur in patients suffering from DLBD, corticobasal 
degeneration (CBD), or prion disease. Prominent frontal deficits 
(executive dysfunction, personality change, disinhibition, apathy, 
lack of empathy, rigid thinking, obsessive-compulsive behaviour 
and development of sweet cravings) are characteristic features 
of frontotemporal variant of frontotemporal lobar degeneration 
(fvFTLD), but may also occur in AD, VCI, progressive supra-
nuclear palsy (PSP), Huntington’s disease (HD) and in some 
rare metabolic and inherited diseases which affect frontal white 
matter or basal ganglia. Problems with speech production (with 
phonemic and grammatical errors) typically occur in PNFA, but 
can also be seen in CBD, PSP and AD, while trouble with nam-
ing and understanding meaning of spoken words is suggestive of 
SD4.
Psychiatric evaluation
Every patient with cognitive impairment should undergo a thor-
ough evaluation of psychiatric symptoms (changes in behaviour, 
delusions and hallucinations, mood changes, neurovegetative 
disorders or personality changes). Behavioural symptoms are 
a characteristic initial sign of fvFTLD when the MMSE score 
may be normal. Some dementias can initially be presented with 
delusions (false belief that is against the reality) and hallucina-
tions (DLBD)1-5. Depressive mood swings as well as depression 
are common in patients suffering from dementia. Other signifi-
cant psychiatric disorders are sleep disturbances (hyposomnia, 
hypersomnia, the day-night cycle reversal, REM sleep behaviour 
disorder in patients with DLBD etc.) and changes in sexual 
behaviour. A craving for sweets is a typical sign of fvFTLD10.
Observing the patient’s behaviour during the examination can 
also be very useful, e.g. psychomotor slowing in patients with 
subcortical syndrome, impulsive behaviour and disinhibition in 
patients with frontal cortical syndrome. Additionally, patients 
with AD preserve the social appearance, but, during the inter-
view, often they tend to turn to their partner to answer the ques-
tions (the “head turning” sign)10.
Neurological examination
Many of the YODs are accompanied with additional neuro-
logical and/or systemic features (dementia plus syndromes). 
Therefore, careful neurological examination is essential in YOD 
(compared to late onset forms) to narrow possible differential 
diagnosis. Although isolated cognitive decline is characteristic for 
AD and FTLD, in YOD the early stage of AD can be accompa-
nied with fine myoclonus14, while FTLD can be presented with 
fasciculations mostly restricted to the deltoid and triceps muscles 
as well as positive primitive reflexes15. The presence of parkinso-
nian symptoms may suggest Parkinson’s disease (PD), DLBD, 
but also other aetiologies such as VCI, PSP, CBD, prion disease, 
HD, Wilson’s disease, neuroacanthocytosis, neurosyphilis, spi-
nocerebellar ataxia (SCA) and other4. Ataxia may occur in VCI, 
vitamin B12 or vitamin E deficiency, exposure to toxins, espe-
cially alcohol, paraneoplastic syndrome, multiple sclerosis (MS), 
coeliac disease, Wilson’s disease, prion disease, SCA and other. 
Pyramidal signs may suggest VCI, MS, vitamin B12 deficiency, 
SCA, mitochondrial or prion disease, neurosyphilis, and other. 
Dystonia and choreoathetosis may suggest HD, CBD, Wilson’s 
disease, prion disease, SCA, dentatorubral-pallidoluysian atrophy 
(DRPLA), and other. „Alien limb“ phenomenon is characteristic 
for CBD, but can also occur in neurosyphilis16. Various different 
ophthalmologic manifestations may occur: retinitis pigmentosa 
suggests mitochondrial disorders; optic atrophy or macular 
degeneration occurs in MS, neurosarcoidosis, vitamin B12 defi-
ciency; retinal microangiopathy is common in diabetes mellitus 
and hypertension (which are risk factors for developing VCI) and 
in vasculitis; supranuclear palsy or gaze palsy suggest PSP, CBD, 
mitochondrial disorders; Kayser-Fleicher ring is a pathognomic 
sign for Wilson’s disease; infection and dryness of the eyes sug-
gest autoimmune connective tissue disease. Seizures may occur 
in AD and VCI or may be a result of a former stroke4. Marche a 
petit pas, i.e., parkinsonism affecting lower limbs accompanied 
with parkinsonian gait (small shuffling steps), with upright 
stance and normal arm swing, is a characteristic of cerebral small 
vessel disease. The classic Hakim’s triad (gait disturbance, urinary 
incontinence, and cognitive decline) is typical for normal pres-
sure hydrocephalus4.
General examination
YOD are more often accompanied with additional systemic 
features (dementia plus syndromes). Certain findings, signs, 
symptoms, and information from patient’s history can indicate 
the aetiology of YOD. Thus, examination of the fundi and blood 
pressure are essential for recognition of vascular disease and 
vascular risk factors. When suspecting paraneoplastic syndrome, 
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breasts, testes, and other potential cancer sites should be exam-
ined. Skin findings may suggest an underlying vasculitis or con-
nective tissue disorder. Cardiac patients (especially patients with 
arrhythmias or patients who have recovered from a heart attack) 
have a higher risk for developing VCI. Some conditions like 
Whipple’s disease or coeliac disease manifest with gastrointesti-
nal disturbance. Liver disease can also lead to cognitive decline 
(subacute haptic encephalopathy)1-5,17.
Neuropsychological assessment
Neuropsychological evaluation is essential in majority of patient 
with YOD. Validated psychological tests enable an objective 
and quantitative insight of the extent and pattern of cognitive 
impairment in an affected subject1-5. Due to their high sensitiv-
ity, neuropsychological tests enable recognition of the cognitive 
decline in the early stages of the disease when screening tests are 
still deficient. Furthermore, neuropsychological tests can evaluate 
the patient’s premorbid functioning, while repeated assessments 
can help monitor the progression/recovery of cognitive defi-
cits1-5,10,12.
Further investigations
The approach to patients suffering from dementia, regardless 
of age, should at the beginning be directed towards recognising 
treatable causes (marked with asterisks in Table 1.)5. In YOD, 
this is of the utmost importance because, in this age group 
potentially reversible causes are more frequent1-5. Furthermore, 
wider differential diagnosis in younger patients requires more 
detailed evaluation. As it is impossible to define an unique diag-
nostic schema, every patient should be approached with an indi-
vidual plan based on the patient’s history, symptoms and findings 
(e.g. evident inherited component requires genotyping early in 
assessment; rapidly progressive dementia or signs of systemic 
disease urge a serum antibody screen, i.e., a screen for autoanti-
bodies, antineural antibodies or antibodies associated with limbic 
encephalitis). According to the American Academy of Neurology 
and European Federation of Neurological Societies every patient 
with YOD should undergo neuroimaging (preferably brain MRI) 
and cerebrospinal fluid (CSF) examination3.4,18,20. Additional 
not frequently used tests (e.g genetic testing, metabolic profil-
ing, testing the activity of white cell enzymes and tissue biopsy) 
should be considered only in specific cases. Despite extensive 
evaluation, the aetiology in YOD often remains unknown even 
in specialized memory clinics. Those patients should be moni-
tored and frequently re-evaluated. 
MRI is the first line diagnostic procedure in YOD. In primary 
neurodegenerative dementias it can show specific localized dis-
tribution of cortical atrophy (e.g. left temporal lobe atrophy in 
SD (Fig. 2), posterior lobe atrophy in PCA (Fig. 3), frontal lobe 
 
 
Figure 2. Brain MRI scan of a 64-year-old patient with semantic dementia showing 
predominant left temporal lobe atrophy. Coronal view.
Figure 3. Brain MRI scan of a 66-year-old patient with posterior cortical atrophy 
showing predominant parietal lobe atrophy. Axial view.
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atrophy in fvFTLD etc.). It may also enable quantitative (using 
volumetric MRI) and semiquantitative (using different scales, 
such as Scheltens scale21) assessment of degree of atrophy (e.g. 
assessment of hippocampal atrophy in AD patients) with the 
possibility of monitoring of progression1-5.
Genetic testing can be done to confirm primary neurodegenera-
tive dementias (e.g. mutations in amyloid precursor protein gene 
(APP) and presenilin genes (PSEN1 and PSEN2) in AD or muta-
tions in MAPT, GRN and C9orf72 genes in FTLD syndrome22). 
Nowadays, genetic testing for most primary neurodegenerative 
diseases are available for in Croatia. Due to high costs of geno-
typing and presence of many mutations, for some aetiologies, 
it is still preferable to establish the diagnosis on the basis of a 
metabolic profile (e.g. increased copper excretion and low cerulo-
plasmin in Wilson’s disease) or direct enzyme assay in leukocytes 
in metabolic disorders presented in adulthood3-4.
Metabolic and molecular brain imaging (especially positron 
emission tomography (PET) using different ligands such as 
fluorodeoxyglucose (FDG) or Pittsburgh B compound (PiB)) 
have an important role in the assessment of highly selected 
patients with YOD, and it is available only in highly specialized 
centres. In patients with AD temporo-parietal hypometabolism 
(and hypoperfusion) can be found on FDG PET (and SPECT) 
imaging of the brain, but this is rarely of greater ancillary value 
comparing to MRI finding of hippocampal atrophy alone3. By 
contrast, hypometabolism on FDG PET may be seen in patients 
with fvFTLD even before MRI shows signs of atrophy3. PET 
imaging with PiB can show in vivo the presence of cerebral amy-
loid depositions in patients with AD and amyloid angiopathy3-4. 
Currently, all these methods are available in Croatia. Costs of 
PET imaging with PiB tracer is covered by health insurance, but 
only for selected patients with YOD. 
In suspicion of paraneoplastic syndromes, the whole-body PET 
scan might be needed in order to detect primary tumour1-5. 
Electroencephalography (EEG) is of value in various encepha-
lopathies, prion diseases and subacute sclerosing panencephalitis 
(showing characteristic changes of periodic complexes)3-4. Early 
slowing or loss of alpha rhythm is a feature of AD, in contrast to 
FTLD, where the alpha rhythm is relatively preserved3.
Examination of the CSF can exclude inflammatory and infec-
tious processes in the central nervous system. In the last decade 
lots of biomarkers emerged that are valuable ancillary tests for 
confirmation of the diagnosis of dementia (e.g. the presence of 
14-3-3 protein with very high concentrations of tau protein is 
supportive of a diagnosis of Creutzfeldt-Jakob disease (CJD); 
decreased amyloid β1-42 and increased phosphorylated and total 
tau proteins have good sensitivity and specificity for AD and are 
also predictive for conversion of mild cognitive impairment to 
AD)3,18-20. Thus, lumbar puncture and measuring three afore-
mentioned CSF biomarkers (amyloid β1-42, phosphorylated and 
total tau proteins) is included in recommendations for diagnos-
ing of all stages of AD (presymptomatic, mild cognitive impair-
ment and overt dementia) from the National Institute on Aging 
and the Alzheimer’s Association workgroup18-20 Currently, CSF 
biomarkers for AD are available in Croatia. Biomarkers for other 
neurodegenerative diseases are still in the research phase.
At the end, tissue biopsy might be needed to establish the 
diagnosis in rare situations (e.g. skin biopsy when suspecting 
Cerebral Autosomal Dominant Arteriopathy with Sub-cortical 
Infarcts and Leukoencephalopathy (CADASIL), muscle biopsy 
including histochemistry and respiratory enzyme analysis can 
confirm a mitochondrial disorder, tonsillar biopsy in patients 
with suspected variant CJD23, brain biopsy when suspecting cer-
ebral vasculitis24, small bowel biopsy for confirming the diagnosis 
of Whipple’s or coeliac disease etc.)1-5. 
Conclusion
YODs have much wider range of different aetiologies. In contrast 
to LODs, treatable causes and positive inherited background 
are more common in YOD. Atypical presentations of common 
degenerative dementias are more frequent then in LOD. There-
fore, routine cognitive evaluation using standard screening tests 
(e.g. MMSE) is usually insufficient, since non-amnestic deficits, 
more often found in these patients can easily be missed. There-
fore, a thorough neurocognitive assessment and a structured and 
rational diagnostic approach is mandatory to ensure early treat-
ment and prevent progression of the disease.
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